Aclarion, Inc. is a US-listed company in the life sciences tools & services industry. Its financial year ends in December.
Loading chart…
Third-party market data · may be delayed
Under review: every model's value for Aclarion, Inc. is far from the share price, which usually points to a data problem (a merger, a share-count change, a one-off) rather than a bargain or a bubble.
Under review: free cash flow after stock pay is not positive. We'll show the comparison once resolved.
Aclarion, Inc. valuation: adjust assumptions and compare models →
What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.
Aclarion has little or no product revenue yet; it used $8m of cash in the twelve months to June 2026. It passes 2 of our 2 financial-health checks.
Our model value for Aclarion is under review, so past values are not shown until it is resolved.
Source: 10-Q filed August 6, 2026 on SEC EDGAR · Financials · Valuation
Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.
Aclarion, Inc.'s trailing-twelve-month revenue grew 33.1% year on year, with a free-cash-flow margin of -9870.9%. Where it stands out: long-term debt as % of assets of 0.0% ranks 1 of 35 life sciences tools & services companies we cover. Where it lags: operating margin of -11592.1% ranks 52 of 52 life sciences tools & services companies we cover.
Current signal Gross margin expanding: TTM gross margin reached 21.8%, up 48.1pp year over year.
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Loading chart…
Third-party market data · may be delayed
Company announcements, filed results and changes that matter to shareholders.
No recent updates are available for ACON from the sources we follow. See filings →
The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.
We value Aclarion, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 10.1%: the 10-year Treasury yield (4.9%) plus a beta of 1.14 times a 4.5% equity risk premium.
| Model | Value per share | In the combined value? |
|---|---|---|
| Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. | ~$0.1 ~$0.1–$0.2 | Left out: out of range vs price (0.03x) |
| Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. | — | Combined value withheld. Review the individual models and their assumptions. |
Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Aclarion, Inc. with Life Sciences Tools & Services in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.
| At fiscal year end | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Share price | $83937.60 | $28944.00 | $1302.48 | $4.60 |
| Market value | $480.5bn | $27m | $1m | $2m |
| + Net debt (− = net cash) | −$1m | −$1m | −$453661 | −$12m |
| Enterprise value | $480.5bn | $26m | $774578 | −$10m |
| Multiples | ||||
| Price / sales | n/m | n/m | 26.9x | 32.3x |
| Price / earnings | — | — | — | — |
| Price / free cash flow | — | — | — | — |
| EV / EBITDA | — | — | — | — |
Weak moat
How hard Aclarion's competitive advantage looks for rivals to wear away, judged from 5 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.
Net income has been a median -150.5% of total assets over 5 years.
Gross margin has been a median -26.4%, moving by 30.9 percentage points (standard deviation) across 5 years.
Operating margin has been a median -10056.7%; its worst year was -11592.1%.
Free cash flow was positive in 0 of 5 years, at a median -9870.9% of revenue.
AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (12 before it).
| Fiscal year | EPS | Growth | Revenue | Growth |
|---|---|---|---|---|
| Current | −$4.51 | +64% | $109470 | +45% |
| Next | −$5.47 | −21% | $245180 | +124% |
The consensus EPS forecast for the current fiscal year is −67.1% on 90 days ago. In the last 30 days, 0 analysts raised Aclarion, Inc.'s forecast and 1 cut it.
Average of analysts' published estimates (third-party data).
| Period | Current fiscal year |
|---|---|
| 90 days ago | −$13.71 |
| 60 days ago | −$4.37 |
| 30 days ago | −$4.37 |
| 7 days ago | −$4.37 |
| Now | −$4.51 |
| Quarter to | Estimate | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | −$1.05 | −$1.12 | −6.7% |
| Mar 2026 | −$1.55 | −$1.34 | +13.6% |
| Dec 2025 | −$3.60 | −$4.52 | −25.6% |
| Sept 2025 | −$2.64 | −$2.93 | −11.0% |
Adjusted EPS as companies report it, against the average analyst estimate.
| Calendar year | 2023 | 2024 | 2025 | 2026 to date |
|---|---|---|---|---|
| Return | ||||
| ACON | −66% | −96% | −100% | −61% |
| Industry peers (median) | −3% | −13% | −2% | +16% |
| S&P 500 | +26% | +25% | +18% | +11% |
| Months that ended higher | ||||
| ACON | 33% | 17% | 42% | 36% |
| S&P 500 | 67% | 75% | 75% | 46% |
| Largest fall from a high during the year | ||||
| ACON | −85% | −97% | −100% | −78% |
| S&P 500 | −10% | −8% | −19% | −9% |
Worst fall since April 22, 2022: 100% from April 22, 2022 to November 2, 2026. Getting back needed a 21868700% gain, and the shares have not yet recovered.
| Results released | Next day | S&P 500 next day | 5 days | 21 days |
|---|---|---|---|---|
| February 21, 2024 | −26.9% | +2.2% | −78.1% | −78.4% |
| August 25, 2023 | −2.2% | +1.3% | +5.0% | −21.7% |
| May 23, 2023 | −10.4% | −1.8% | +46.1% | +37.8% |
| May 16, 2023 | −2.3% | +0.5% | −17.8% | +64.9% |
Source: SEC EDGAR filings. Retrieved October 29, 2026.
| Period | Revenue (TTM) |
|---|---|
| FY23 Q3 | $84.1K |
| FY23 Q4 | $75.4K |
| FY24 Q1 | $60K |
| FY24 Q2 | $53.9K |
| FY24 Q3 | $49.3K |
| FY24 Q4 | $45.7K |
| FY25 Q1 | $54.6K |
| FY25 Q2 | $62.9K |
| FY25 Q3 | $67.5K |
| FY25 Q4 | $75.7K |
| FY26 Q1 | $77.9K |
| FY26 Q2 | $83.8K |
Source: SEC EDGAR filings. Retrieved October 29, 2026.
| Period | Revenue growth, TTM YoY |
|---|---|
| FY23 Q3 | 68.6% |
| FY23 Q4 | 24.8% |
| FY24 Q1 | -21.9% |
| FY24 Q2 | -35.2% |
| FY24 Q3 | -41.4% |
| FY24 Q4 | -39.4% |
| FY25 Q1 | -9.1% |
| FY25 Q2 | 16.7% |
| FY25 Q3 | 36.9% |
| FY25 Q4 | 65.6% |
| FY26 Q1 | 42.6% |
| FY26 Q2 | 33.1% |
Source: SEC EDGAR filings. Retrieved October 29, 2026.
| Period | Operating margin (TTM) |
|---|---|
| FY23 Q3 | -5577.4% |
| FY23 Q4 | -6466.5% |
| FY24 Q1 | -8276.8% |
| FY24 Q2 | -8711.1% |
| FY24 Q3 | -9805.8% |
| FY24 Q4 | -12057.2% |
| FY25 Q1 | -10493.7% |
| FY25 Q2 | -10056.7% |
| FY25 Q3 | -10173.7% |
| FY25 Q4 | -9312.4% |
| FY26 Q1 | -10975.1% |
| FY26 Q2 | -11592.1% |
Source: SEC EDGAR filings. Retrieved October 29, 2026.
| Period | FCF margin (TTM) |
|---|---|
| FY23 Q3 | -5002.4% |
| FY23 Q4 | -5052.3% |
| FY24 Q1 | -8394.6% |
| FY24 Q2 | -9552.2% |
| FY24 Q3 | -10682.3% |
| FY24 Q4 | -11951.6% |
| FY25 Q1 | -10525.5% |
| FY25 Q2 | -10346.2% |
| FY25 Q3 | -9818.4% |
| FY25 Q4 | -9691.6% |
| FY26 Q1 | -9599.8% |
| FY26 Q2 | -9870.9% |
| Fiscal year | 2021 Dec 2021 | 2022 Dec 2022 | 2023 Dec 2023 | 2024 Dec 2024 | 2025 Dec 2025 | LTM Jun 2026 |
|---|---|---|---|---|---|---|
| Income | ||||||
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross profit | −0 | −0 | −0 | −0 | 0 | 0 |
| EBITDA | −3 | −5 | −5 | −5 | −7 | −10 |
| Operating income | −3 | −6 | −5 | −6 | −7 | −10 |
| Net income | −5 | −7 | −5 | −7 | −7 | −9 |
| Diluted EPS | −$0.44 | −$1.31 | −$5318.80 | −$7478.90 | −$13.61 | — |
| Growth (year on year) | ||||||
| Revenue | — | +0.3% | +24.8% | −39.4% | +65.6% | +33.1% |
| Margins | ||||||
| Gross margin | −14.7% | −8.0% | −0.4% | −85.2% | 9.0% | 21.8% |
| EBITDA margin | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% |
| Operating margin | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% |
| Net margin | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% |
| Free-cash-flow margin | — | — | <−999% | <−999% | <−999% | — |
| Cash flow | ||||||
| Cash from operations | −2 | −5 | −4 | −5 | −7 | −8 |
| Capital spending | — | — | 0 | 0 | 0 | — |
| Free cash flow | — | — | −4 | −5 | −7 | — |
| Stock-based pay | 0 | 1 | 0 | 0 | 0 | 0 |
| Free cash flow after stock pay | — | — | −4 | −6 | −7 | — |
| Balance sheet | ||||||
| Cash | 0 | 1 | 1 | 0 | 12 | 16 |
| Total debt | 2 | 0 | 0 | 0 | 0 | 0 |
| Net debt (negative = net cash) | 2 | −1 | −1 | −0 | −12 | −16 |
| Diluted shares | 14m | 6m | — | — | — | — |
| Returned to shareholders | ||||||
| Buybacks | 0 | — | — | — | — | — |
| Total returned | 0 | — | — | — | — | — |
| Quarter | 2024 Q3 Sept 2024 | 2024 Q4 Dec 2024 | 2025 Q1 Mar 2025 | 2025 Q2 Jun 2025 | 2025 Q3 Sept 2025 | 2025 Q4 Dec 2025 | 2026 Q1 Mar 2026 | 2026 Q2 Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Income | ||||||||
| Revenue | 14 | 10 | 19 | 19 | 19 | 18 | 21 | 25 |
| Gross profit | −7 | −10 | −4 | 5 | 4 | 2 | 4 | 8 |
| EBITDA | −1,246 | −1,754 | −1,437 | −1,736 | −1,773 | −1,932 | −2,926 | −2,898 |
| Operating income | −1,296 | −1,806 | −1,492 | −1,737 | −1,831 | −1,993 | −2,987 | −2,900 |
| Net income | −1,366 | −1,990 | −2,037 | −1,601 | −1,706 | −1,889 | −2,854 | −2,748 |
| Diluted EPS | −$1321.49 | −$1585.25 | −$9.32 | −$2.75 | −$2.93 | −$2.01 | −$1.34 | −$1.12 |
| Growth (year on year) | ||||||||
| Revenue | −24.4% | −25.8% | +87.8% | +76.1% | +31.5% | +80.6% | +11.3% | +30.5% |
| Margins | ||||||||
| Gross margin | −48.1% | −100.9% | −23.6% | 26.6% | 23.2% | 9.7% | 17.7% | 32.9% |
| EBITDA margin | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% |
| Operating margin | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% |
| Net margin | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% |
| Free-cash-flow margin | <−999% | <−999% | — | — | <−999% | <−999% | — | <−999% |
| Cash flow | ||||||||
| Cash from operations | −1,056 | −923 | −2,511 | −1,866 | −1,160 | −1,627 | −2,642 | −2,657 |
| Capital spending | 0 | 5 | — | — | 7 | 14 | — | 0 |
| Free cash flow | −1,056 | −928 | — | — | −1,168 | −1,641 | — | −2,657 |
| Stock-based pay | 75 | 57 | 56 | 28 | 17 | 4 | 5 | 102 |
| Free cash flow after stock pay | −1,130 | −985 | — | — | −1,184 | −1,646 | — | −2,759 |
| Last 12 months unless stated | ACON | ISPC | YDES | QSI | BGLC | SEER | Median |
|---|---|---|---|---|---|---|---|
| Revenue, last 12 months | $83769 | $466302 | $596817 | $2m | $3m | $14m | $229m |
| Revenue growth, last 12 months | 33.1% | −92.1% | 16.9% | −53.0% | −67.3% | −12.7% | 6.9% |
| Revenue growth, 3-year average | 0.2% | −64.1% | — | 51.8% | −32.9% | −5.1% | 2.9% |
| Revenue growth, latest quarter | 30.5% | −78.7% | — | −41.8% | −96.6% | −23.4% | 8.5% |
| Gross margin | 21.8% | −98.0% | 28.1% | 35.0% | 12.3% | 47.7% | 51.9% |
| Operating margin | <−999% | <−999% | −883.3% | <−999% | −81.8% | −498.2% | −14.3% |
| Operating margin, 3-year average | <−999% | −768.0% | — | <−999% | −45.3% | −575.4% | −22.4% |
| Net margin | <−999% | <−999% | <−999% | <−999% | −82.4% | −478.0% | −16.1% |
| Cash from operations / revenue | <−999% | <−999% | <−999% | <−999% | −27.1% | −305.1% | 1.3% |
| Free-cash-flow margin | <−999% | <−999% | <−999% | <−999% | −27.3% | −311.1% | −2.2% |
| Free-cash-flow margin, 3-year average | <−999% | −549.8% | — | <−999% | −29.5% | −335.4% | 0.6% |
| Stock pay / revenue | 152.7% | 1.0% | 75.1% | 693.5% | — | 74.3% | 4.4% |
| Change in share count | — | — | 3.1% | 31.2% | — | 0.2% | 1.0% |
| Measure | Company | Peer median | Rank |
|---|---|---|---|
| Revenue growth Growth | 33.1% | 6.9% | 5 of 54 |
| Change in growth rate Growth | -9.6pp | +0.4pp | 50 of 54 |
| Gross margin Profitability | 21.8% | 52.0% | 41 of 45 |
| Operating margin Profitability | -11592.1% | -14.3% | 52 of 52 |
| Net margin Profitability | -10978.5% | -12.2% | 54 of 54 |
| Free-cash-flow margin Cash generation | -9870.9% | -1.3% | 54 of 54 |
| Stock pay as % of revenue Cash generation | 152.7% | 4.4% | 52 of 53 |
| Long-term debt as % of assets Balance sheet | 0.0% | 26.3% | 1 of 35 |
| Days sales outstanding Balance sheet | 123 days | 62 days | 47 of 48 |
Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).
| Manager | Value | Shares | Share of 13F value | Shares QoQ |
|---|---|---|---|---|
| Bridgeway Capital Management, LLC | $56,102 | 19K | 16.9% | New |
| Captrust Financial Advisors | $49,130 | 17K | 14.8% | ▲ 17.2% |
| Vanguard Fiduciary Trust Co | $46,161 | 16K | 13.9% | New |
| Susquehanna International Group, LLP | $44,222 | 15K | 13.3% | New |
| Geode Capital Management, LLC | $34,927 | 12K | 10.5% | ▼ 61.1% |
| Xtx Topco Ltd | $31,789 | 11K | 9.6% | New |
| Bank Of Montreal | $28,800 | 10K | 8.7% | 0.0% |
| Vanguard Capital Management LLC | $19,532 | 7K | 5.9% | 0.0% |
| Osaic Holdings, Inc. | $14,400 | 5K | 4.3% | ▼ 85.7% |
| UBS Group AG | $5,668 | 2K | 1.7% | ▼ 79.6% |
| Barclays PLC | $815 | 0K | 0.2% | New |
| Clear Street Group Inc. | $297 | 0K | 0.1% | ▲ 3333.3% |
From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Aclarion, Inc.'s complete shareholder register. Values are as reported by the filers .
| Insider | Date | Trade | Shares | Price | Value |
|---|---|---|---|---|---|
| Williams Amanda M Director | August 17, 2026 | Buy | 5,857 | $2.73 | $15,990 |
| Gould Gregory A CFO | August 14, 2026 | Buy | 10,000 | $2.45 | $24,500 |
| Ness Brent Chief Executive Officer | August 13, 2026 | Buy | 5,234 | $2.31 | $12,091 |
| Neal David K Director | August 13, 2026 | Buy | 7,500 | $2.40 | $18,000 |
| Wesemann William Director | August 13, 2026 | Buy | 2,150 | $2.34 | $5,031 |
| Bond Ryan Director | August 13, 2026 | Buy | 21,122 | $2.37 | $50,059 |
| Breidbart Scott Director | May 12, 2026 | Buy | 5,664 | $3.18 | $18,012 |
| Ness Brent Chief Executive Officer | May 11, 2026 | Buy | 6,289 | $3.18 | $19,999 |
| Neal David K Director | May 11, 2026 | Buy | 2,500 | $3.10 | $7,750 |
| Wesemann William Director | May 6, 2026 | Buy | 1,562 | $3.30 | $5,155 |
| Ness Brent Chief Executive Officer | November 26, 2025 | Buy | 10 | $6.20 | $62 |
From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
Next expected around May 14, 2024 estimated from the company's past filing pattern, not announced
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| Financial statements | SEC 10-K and 10-Q filings | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
New research on the companies we cover arrives in the weekly email. Free, one email a week.
